The mark consists of CliniSelect PG is a novel hardware and software tool equipped with a web-browseable methodology to enable Phase III pharmaceutical clinical trial services (PCTS) following post-genomics (PG) specifications and requirements, where the right patients for the right disease state are included. The hardware and software components bring together specific disease profiles, patient demographics, genotype profiles of matched healthy and afflicted subjects, and related queriable knowledgebase. Such PG-oriented knowledgebase can be screened against a given set of "inclusion/ exclusion criteria" for the choice of best-suited sub-populations for Phase III PCTS. CliniSelect PG functionality ingeniously connects healthcare centers and PCTS sponsors (pharma companies, government health organizations) to complete Phase III human clinical trials in the PG-based drug development..
CLINICAL SELECT POST GENOMICS
Trademark: 78422317
